Genzyme crunches consent-decree fine numbers; SAFC expands for dry powder media;

> Genzyme says it anticipates a $175-million penalty in the forthcoming FDA consent decree for its Boston area manufacturing plant, in addition to percentage-of-revenue fines for any operations-corrections deadlines it misses going forward. Genzyme release

> Sigma-Aldrich company SAFC is spending $6.15 million to expand its Lenexa, KS, facility for the upstream and downstream production of dry powder media and reagents. SAFC release

> Former FDA commissioner Andrew von Eschenbach has joined the scientific advisory board of nanotechnology company Arrowhead Research. Arrowhead release

> The Chao Center for Industrial Pharmacy and Contract Manufacturing at Purdue Research Park is closing its doors. Item

> Kimberly-Clark Professional has introduced the Kimtech Pure G3 and G5 sterling nitrile cleanroom gloves. Article

Suggested Articles

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S. 

After months of delay for ultra-pricey gene therapy Zynteglo, Bluebird Bio is hoping to dose its first German patients in the first half of the year.

North Carolina is providing some financial assistance for the construction of Audentes gene therapy facility in Sanford, North Carolina. (Astellas)